Acute stress reaction
Methodology & AI Transparency ⓘ
Acute stress reaction Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Clinical coding for Acute stress reaction uses ICD-10 F43.0 across Anxiety & PTSD specialty care.
- 3 Typical cash cost range: Primary evaluation for Acute stress reaction incorporates functional impairment review [Acute stress reaction F43.0] and symptom diary review.
- 4 Top reported side effects / signs: Key Anxiety & PTSD biomarkers for Acute stress reaction (F43.0): TSH & Ferritin in Acute stress reaction (F43.0: Rule-Out) & GAD-7 Anxiety Severity in Acute stress reaction (F43.0: Score) (< 4 (minimal anxiety) (F43.0)).
Ask our AI Specialists anything about Acute stress reaction
What Is Acute stress reaction?
Recognized across U.S. clinical coding as F43.0 (Anxiety & PTSD), Acute stress reaction is evaluated via functional impairment review [Acute stress reaction F43.0] to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Acute stress reaction (F43.0, Anxiety & PTSD) reflects autonomic vagal withdrawal [Acute stress reaction F43.0]. longitudinal control is benchmarked via TSH & Ferritin in Acute stress reaction (F43.0: Rule-Out).
Common Symptoms & Clinical Signs
- • Presentation of Acute stress reaction (F43.0): avoidance of triggers, in Acute stress reaction (F43.0: intrusive trauma memories,)
- • Secondary Acute stress reaction clinical sign: excessive, hard-to-control anticipatory in Acute stress reaction (F43.0: worry or intrusive)
- • Symptom flares in Acute stress reaction correlating with TSH & Ferritin in Acute stress reaction (F43.0: Rule-Out) deviation outside TSH 0.8–2.5 mIU/L; Ferritin > 50 ng/mL (F43.0)
- • Functional anxiety & ptsd impact requiring functional impairment review [Acute stress reaction F43.0] evaluation (F43.0)
Acute stress reaction Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F43.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Anxiety, OCD & Trauma Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: TSH & Ferritin in Acute stress reaction (F43.0: Rule-Out) | TSH 0.8–2.5 mIU/L; Ferritin > 50 ng/mL (F43.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: GAD-7 Anxiety Severity in Acute stress reaction (F43.0: Score) | < 4 (minimal anxiety) (F43.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Resting Heart Rate in Acute stress reaction (F43.0: Variability (HRV)) | Stable upward personal trend (F43.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Acute stress reaction
Treatment selection for Acute stress reaction depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Acute stress reaction)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Intermittent or Continuous kidney-Replacement Therapy in Acute Kidney Indexed from New England Journal of Medicine (2026-10-14) by DotMD's 2-hour clinical surveillance pipeline. New England Journal of Medicine • 2026-10-14 • Peer-Reviewed Journal (Clinical Trials) | Multi-cohort | 97/100 | PMID NEJM-62256824 ↗ |
| New Insights on Baseline data, initial course, and management: losartan versus captopril: What a 5,477-Participant Study Found A total of 5,477 patients with heart failure during the acute phase or with a new Q-wave anterior infarction or reinfarction were recruited. The American journal of cardiology • 2001-03-15 • Randomized Controlled Trial | N = 5,477 | 96/100 | PMID 11249900 ↗ |
| New Insights on Evaluating the real-world benefits and safety of SpikoGen®, an: What a 4,219-Participant Study Found 12 657 and 4219 participants were randomized to the SpikoGen® and placebo group and followed for a median of 55 days (interquartile range, 48-60 days) and 51 days. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases • 2023-02-15 • Phase III Randomized Trial | N = 4,219 | 96/100 | PMID 36096430 ↗ |
| New Insights on Reductions in acute medication use and healthcare resource utilization in: What a 1,113-Participant Study Found Treatment with galcanezumab resulted in significant reductions in headache medication overuse and migraine headache days requiring acute medication use, with notable reductions in migraine-specific HCRU. Journal of medical economics • 2022-01-15 • Phase III Randomized Trial | N = 1,113 | 96/100 | PMID 35971655 ↗ |
| New Insights on Comparative Efficacy of Statins for Prevention of Contrast-Induced Acute Kidney: What a 6,385-Participant Study Found Results showed that statin loading before contrast administration was associated with a significantly reduced risk of CI-AKI in patients with CKD undergoing cardiac catheterization (odds ratio: 0.46; P < .05). Angiology • 2019-04-15 • Meta-Analysis | N = 6,385 | 94/100 | PMID 30261736 ↗ |
Acute stress reaction Patient Community & “People Like Me” Threads
Filter Acute stress reaction community threads and patient logs by age, biological sex, dosage, and treatment duration.